Monday, Jan 28, 2002

Genentech Names Mark Ahn Vice President, Hematology Sales and Marketing

South San Francisco, Calif. -- January 28, 2002 --

Genentech, Inc. (NYSE: DNA) today announced the appointment of Mark Ahn to vice president, Hematology Sales and Marketing. Ahn will report to Myrtle Potter, executive vice president of Commercial Operations and chief operating officer.

In his position, Ahn, 39, is responsible for all commercial activities, including sales and marketing, of the company's hematology franchise, including Rituxan® (rituximab) for non-Hodgkin's lymphoma.

"Mark's extensive biotechnology and pharmaceutical experience will be an asset to Genentech's Commercial organization," said Potter. "I'm confident that he will help Genentech continue to build its hematology franchise, an important and promising area of our business."

Prior to joining Genentech, Ahn was senior director of immunology sales for Bristol-Myers Squibb (BMS). In addition, he led the Secure the Future initiative, a $100 million commitment by Bristol-Myers Squibb to provide care and support for women and children living with HIV/AIDS in sub-Saharan Africa. Before that Ahn was responsible for strategic planning for international operations, and worked with Japan and China operations. Prior to BMS, he was at Amgen Inc. where he served as General Manager, Amgen Greater China and held positions in strategy, general management, sales and marketing, business development and finance. Ahn also served as an officer in the U.S. Army.

Ahn holds a bachelor's degree in history/economics and a master's of business administration in finance from Chaminade University. He was a graduate fellow in economics at Essex University, and has a doctorate in business administration from the University of South Australia.

Genentech, Inc., is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Fifteen of the currently approved products of biotechnology are based on or stem from Genentech science. Genentech markets ten products directly in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA.

# # #